YS Stock Forecast 2025-2026
Distance to YS Price Targets
YS Price Momentum
10 Quality Stocks Worth Considering Now
Researching Ys Biopharma (YS) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on YS and similar high-potential opportunities.
Latest YS Stock Price Targets & Analyst Predictions
YS has shown a year-to-date change of -44.6% and a 1-year change of 177.8%, reflecting upward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for YS. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
YS Analyst Ratings
YS Price Target Range
Latest YS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for YS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 13, 2023 | Noble Capital Markets | Gregory Aurand | Outperform | Initiates | $5.25 |
Ys Biopharma Co Ltd. (YS) Competitors
The following stocks are similar to Ys Biopharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Ys Biopharma Co Ltd. (YS) Financial Data
Ys Biopharma Co Ltd. has a market capitalization of $192.09M with a P/E ratio of -0.7x. The company generates $75.03M in trailing twelve-month revenue with a -66.8% profit margin.
Revenue growth is -9.2% quarter-over-quarter, while maintaining an operating margin of -49.5% and return on equity of -77.8%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Ys Biopharma Co Ltd. (YS) Business Model
About Ys Biopharma Co Ltd.
Develops vaccines and therapeutic biologics.
YS Biopharma Co., Ltd. generates revenue by discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics aimed at infectious diseases and cancer. The company employs its proprietary PIKA immunomodulating technology platform to create products such as the PIKA rabies vaccine and PIKA recombinant COVID-19 vaccine.
Founded in 2002 and headquartered in Beijing, YS Biopharma operates internationally in markets including China, the United States, Singapore, the United Arab Emirates, and the Philippines, positioning itself as a significant player in the biopharmaceutical sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
773
CEO
Dr. Hui Shao C.F.A., M.B.A., Ph.D.
Country
China
IPO Year
2021
Website
www.ysbiopharm.comYs Biopharma Co Ltd. (YS) Latest News & Analysis
YS Biopharma Co., Ltd. announced news from Gaithersburg, Md., on May 24, 2024. Further details about the announcement were not provided in the excerpt.
YS Biopharma's announcement may indicate new developments or partnerships that could impact its stock performance, innovation pipeline, and market position, influencing investment decisions.
YS Biopharma Co., Ltd. announced news on May 21, 2024, from Gaithersburg, Md. Further details were not provided in the excerpt.
YS Biopharma's news may indicate developments in biotech that could affect stock performance, partnerships, or innovations, influencing investment strategies in the sector.
YS Biopharma Co., Ltd. announced news on May 7, 2024, from Gaithersburg, Md. Further details were not provided in the excerpt.
YS Biopharma's developments may impact stock performance, market positioning, and investor sentiment, influencing investment decisions in the biopharma sector.
YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
10 months agoYS Biopharma Co., Ltd. announced news on April 29, 2024, in Gaithersburg, Maryland. Further details were not provided in the excerpt.
YS Biopharma's news may indicate developments in their product pipeline or financial performance, impacting stock valuation and market sentiment among investors in the biotech sector.
YS Biopharma Co., Ltd. (NASDAQ:YS) will hold its Q3 2024 Earnings Conference Call on April 19, 2024, at 8:00 AM ET, featuring key executives including the CEO and CFO.
YS Biopharma's Q3 earnings call indicates financial performance and strategic direction, influencing stock valuation and investor sentiment in the biotech sector.
YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024
10 months agoYS Biopharma Co., Ltd. announced news from Gaithersburg, Md. on April 19, 2024. Further details on the announcement are not provided in the excerpt.
YS Biopharma's news could indicate developments in biotech, impacting stock performance and investor sentiment in the healthcare sector. Watch for potential innovations or partnerships.
Frequently Asked Questions About YS Stock
What is Ys Biopharma Co Ltd.'s (YS) stock forecast for 2025?
Based on our analysis of 1 Wall Street analysts, Ys Biopharma Co Ltd. (YS) has a median price target of $4.17. The highest price target is $5.25 and the lowest is $3.10.
Is YS stock a good investment in 2025?
Analyst ratings for YS are not currently available. The stock is currently trading at $2.00. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for YS stock?
Wall Street analysts predict YS stock could reach $4.17 in the next 12 months. This represents a 108.5% increase from the current price of $2.00. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Ys Biopharma Co Ltd.'s business model?
YS Biopharma Co., Ltd. generates revenue by discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics aimed at infectious diseases and cancer. The company employs its proprietary PIKA immunomodulating technology platform to create products such as the PIKA rabies vaccine and PIKA recombinant COVID-19 vaccine.
What is the highest forecasted price for YS Ys Biopharma Co Ltd.?
The highest price target for YS is $5.25 from Gregory Aurand at Noble Capital Markets, which represents a 162.5% increase from the current price of $2.00.
What is the lowest forecasted price for YS Ys Biopharma Co Ltd.?
The lowest price target for YS is $3.10 from at , which represents a 55.0% increase from the current price of $2.00.
What is the overall YS consensus from analysts for Ys Biopharma Co Ltd.?
Analyst ratings for YS are not currently available. The stock is trading at $2.00.
How accurate are YS stock price projections?
Stock price projections, including those for Ys Biopharma Co Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
